Knight Therapeutics Inc. (FRA:04K)

Market Cap	728.15M +104.6%
Revenue (ttm)	337.34M +42.3%
Net Income	9.17M +3,782.8%
EPS	0.10 +8,835.1%
Shares Out	n/a
PE Ratio	77.51
Forward PE	115.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	7.40
Previous Close	7.40
Day's Range	7.40 - 7.40
52-Week Range	3.52 - 7.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 830
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 04K

Financial Performance

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error